Leading drug companies such as Novartis and Sanofi paid him from 1996 to conduct trials of anti-psychotic drugs on patients with schizophrenia and Alzheimer's disease.
He worked as a consultant psychiatrist for the South London and Maudsley NHS Trust and recruited patients in Kent and parts of the capital for the research, according to reports.
His position at the institute helped him to secure funding, said to be almost one million pounds, from five drug companies. Most of the money was channelled through a private company that he had set up called Psychmed.
The Association of the British Pharmaceutical Industry asked the GMC to examine his conduct two years ago after concerns that he had failed to obtain proper approval from ethical committees to conduct the tests.
These approvals are vital in any trial to protect the patients taking part.
Source-ANI
SRM/S